NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares) Stock Analysis - Politician Trades

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is a publicly traded Healthcare sector company. As of May 21, 2026, NAMS trades at $35.77 with a market cap of $3.99B and a P/E ratio of -20.07. NAMS moved +6.11% today. Year to date, NAMS is +6.78%; over the trailing twelve months it is +84.75%. Its 52-week range spans $14.06 to $42.21. Analyst consensus is strong buy with an average price target of $48.00. Rallies surfaces NAMS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded NAMS stock?

Rallies tracks politician and congressional stock disclosures for NAMS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

NAMS Key Metrics

Key financial metrics for NAMS
MetricValue
Price$35.77
Market Cap$3.99B
P/E Ratio-20.07
EPS$-1.79
Dividend Yield0.00%
52-Week High$42.21
52-Week Low$14.06
Volume1.15M
Avg Volume0
Revenue (TTM)$22.57M
Net Income$-212.73M
Gross Margin0.00%

Latest NAMS News

Recent NAMS Insider Trades

  • LANGE LOUIS G sold 44.17K (~$1.34M) on Mar 11, 2026.
  • LANGE LOUIS G sold 446 (~$13.93K) on Mar 11, 2026.
  • Kastelein Johannes Jacob Pieter sold 101.41K (~$3.07M) on Mar 9, 2026.

NAMS Analyst Consensus

11 analysts cover NAMS: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $48.00.

Common questions about NAMS

Which politicians traded NAMS stock?
Rallies tracks politician and congressional stock disclosures for NAMS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in NAMS?
Yes. Rallies tracks politician and congressional stock disclosures for NAMS, including reported purchases, sales, dates, owners, and trade amounts when available.
Is NAMS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NAMS. It does not provide personalized investment advice.
NAMS

NAMS